Advertisement
U.S. markets closed
  • S&P 500

    5,088.80
    +1.77 (+0.03%)
     
  • Dow 30

    39,131.53
    +62.43 (+0.16%)
     
  • Nasdaq

    15,996.82
    -44.78 (-0.28%)
     
  • Russell 2000

    2,016.69
    +2.85 (+0.14%)
     
  • Crude Oil

    76.57
    +0.08 (+0.10%)
     
  • Gold

    2,045.80
    -3.60 (-0.18%)
     
  • Silver

    22.98
    -0.01 (-0.03%)
     
  • EUR/USD

    1.0820
    -0.0007 (-0.06%)
     
  • 10-Yr Bond

    4.2600
    -0.0670 (-1.55%)
     
  • GBP/USD

    1.2672
    +0.0014 (+0.11%)
     
  • USD/JPY

    150.4200
    -0.0800 (-0.05%)
     
  • Bitcoin USD

    51,716.71
    +205.80 (+0.40%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,706.28
    +21.79 (+0.28%)
     
  • Nikkei 225

    39,098.68
    +836.48 (+2.19%)
     

Conformis Reports Second Quarter 2022 Financial Results

Conformis, Inc.
Conformis, Inc.

BILLERICA, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ:CFMS), an orthopedic medical device company that features personalized knee and hip replacement products, announced today financial results for the second quarter ended June 30, 2022.

Second Quarter 2022 Summary

  • Total revenue of $15.3 million. Total revenue in the second quarter of 2021 included significant non-recurring royalty revenue.

  • Product revenue of $15.1 million, remained flat year-over-year on a reported basis and increased 1% on a constant currency basis.

  • Conformis hip system revenue of $0.7 million, a decrease of 18% year-over-year.

  • Cash and cash equivalents of $72.6 million as of June 30, 2022.

Executive Commentary – Mark Augusti, President and CEO

“Our second quarter results show signs that we are on the right long-term path. We were in-line with our revenue expectations for the quarter and continued to grow our Imprint case volume. The recent signing of our first national agreement for our new Platinum Services Program highlights that our portfolio shift is taking hold. Like many companies, we continue to deal with macro-economic and supply chain challenges that have impacted our business. In light of this, I’m pleased with the recent progress we have made on expense management. These efforts when combined with the continued positive surgeon feedback keep us confident in our long-term strategy.”

 

 

 

 

Three months ended June 30,

Increase/(decrease)

($, in thousands)

 

2022

 

2021

$ Change

% Change

% Change

 

 

 

 

(as reported)

(constant currency)

United States

$

13,415

$

13,424

$

(9

)

—%

—%

Rest of world

 

1,727

 

1,775

 

(48

)

(3)%

6%

Product revenue

 

15,142

 

15,199

 

(57

)

—%

1%

Royalty revenue

 

153

 

41,149

 

(40,996

)

(100)%

(100)%

Total revenue

$

15,295

$

56,348

$

(41,053

)

(73)%

(73)%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Second Quarter 2022 Highlights

Revenue

  • Product revenue remained flat year-over-year.

  • Royalty and licensing revenue decreased year-over-year as a result of $41.0 million of royalty and licensing revenue recognized in the prior year related to non-recurring patent license settlement and development agreements.

Gross Margin

  • Product gross profit margin was 35.1% in the second quarter of 2022, compared to 42.0% in the same period last year. The gross margin rate declined year-over-year as a result of higher labor and material costs, operational inefficiencies as we transition to our new business model, higher cancelled case inventory expense, and a reduction in selling price.

  • Total gross profit was $5.5 million for the second quarter of 2022, compared to $47.5 million in the same period last year. The second quarter of 2021 included $41.0 million of non-recurring royalty and license revenue.

Operating Expenses

  • Total operating expenses of $18.2 million, an increase of $1.6 million year-over-year.

  • Sales and marketing expenses increased $0.3 million primarily due to higher personnel, marketing, and training costs partially offset by lower commissions expense.

  • Research and development expenses increased $0.3 million primarily driven by higher revenue share expense and project-related costs for our new hip stem, porous coated knee, and design software enhancements.

  • General and administrative expenses increased $1.0 million primarily driven by higher customer delivery related costs and professional fees related to litigation involving our intellectual property.

Net Loss

  • Net loss was $15.5 million, or $0.09 per basic and diluted share, in the second quarter of 2022, compared to a net income of $38.0 million, or $0.21 per basic and diluted share, in the same period last year.

  • Foreign currency exchange transaction loss was $2.4 million in the second quarter of 2022, compared to foreign currency exchange transaction income of $0.5 million in the same period last year.

  • Weighted average basic and diluted shares outstanding of 180.3 million for the second quarter of 2022, compared to weighted average basic and diluted shares outstanding of 177.7 million and 180.0 million respectively, for the same period last year.

Capital Structure and Liquidity

  • Cash and cash equivalents totaled $72.6 million as of June 30, 2022, compared to $100.6 million as of December 31, 2021.

Outlook

  • We expect our third quarter product revenue to be in the range of $13.0 million to $14.0 million.

  • We are updating our full year product revenue expectations to a range of $57 million to $61 million.

  • For operating expenses, we now expect to be at the low end of our previous guidance range of $75 million to $81 million for the year.

Note on Non-GAAP Financial Measures

In addition to disclosing financial measures prepared in accordance with U.S. generally accepted accounting principles (GAAP), the Company provides certain information regarding the Company's financial results or projected financial results on a non-GAAP "constant currency basis." This information estimates the impact of changes in foreign currency rates on the translation of the Company's current or projected future period financial results as compared to the applicable comparable period. This impact is derived by taking the adjusted current or projected local currency results and translating them into U.S. dollars based upon the foreign currency exchange rates for the applicable comparable period. It does not include any other effect of changes in foreign currency rates on the Company's results or business. Non-GAAP information is not a substitute for, and is not superior to, information presented on a GAAP basis. Company management uses these non-GAAP measures internally to measure operational performance.

Conference Call and Webcast – August 9, 2022 – 8:30 am ET

As previously announced, Mark Augusti, CEO, and Bob Howe, CFO, will host a webcast and conference call, Tuesday, August 9, 2022, at 8:30 a.m. Eastern Time to discuss this business update.

The webcast of the earnings call will be live at: https://edge.media-server.com/mmc/p/yu9ig355

To attend by telephone, please use the information below for dial-in access.

  • Date and Time: August 9, 2022 – 8:30 a.m. Eastern Time

  • Please register for the call. You can register any time.

  • Link to register: https://register.vevent.com/register/BI5bc093e635aa4a84b04d7d3925d2dd0d

  • Registration in advance is encouraged. You can then choose to be provided with the dial-in and PIN or to use the new “Call Me” feature.

The webcast will be live at: https://edge.media-server.com/mmc/p/yu9ig355
To attend by telephone, please use the information below for dial-in access.

  • When prompted on dial-in, please utilize conference ID: 9056628

  • Participant conference numbers: (877) 809-6331 (U.S./Canada) and (615) 247- 0224 (International).

  • Please dial in at least 10 minutes before the call to ensure timely participation.

The online archive of the webcast will be available on the company’s website at ir.conformis.com for 30 days.

About Conformis, Inc.

Conformis is a medical technology company focused on advancing orthopedic patient care and creating a world without joint pain. Its product portfolio is designed to maximize surgeon and patient choice by offering fully personalized solutions through its Image-to-Implant® Platinum Services℠ Program as well as data-informed, standardized solutions that combine many benefits of personalization with the convenience and flexibility of an off-the-shelf system. Conformis’ sterile, just-in-time, Surgery-in-a-Box™ delivery system is available with all of its implants and personalized, single-use instruments. Conformis owns or exclusively in-licenses issued patents and pending patent applications that cover personalized implants and patient-specific instrumentation for all major joints.

For more information, visit www.conformis.com. To receive future releases in e-mail alerts, sign up at ir.conformis.com.

Cautionary Statement Regarding Forward-Looking Statements

Statements in this press release about our future expectations, plans and prospects, the anticipated timing of our product launches, and our financial position and results, total revenue, product revenue, gross margin, operations and growth, as well as other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "predict," "project," "should," "target," "will," or "would" or the negative of these terms or other and similar expressions are intended to identify forward-looking statements within the meaning of the safe harbor provisions of The Private Securities Litigation Reform Act of 1995, although not all forward-looking statements contain these identifying words. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make as a result of a variety of risks and uncertainties, including risks related to the novel coronavirus pandemic and the response to the pandemic; whether our cash resources will be sufficient to fund our continuing operations for the periods anticipated; risks related to our estimates and expectations regarding our revenue, gross margin, expenses, revenue growth and other results of operations, and the other risks and uncertainties described in the "Risk Factors" sections of our Annual Report on Form 10-K for the fiscal year ended December 31, 2021, Quarterly Report on Form 10-Q for the fiscal quarters ended March 31, 2022 and June 30, 2022, and other public filings with the U.S. Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent our views as of the date hereof. We anticipate that subsequent events and developments may cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date hereof.

CONTACT:
Investor Relations
ir@conformis.com
(781) 374-5598


 

CONFORMIS, INC. AND SUBSIDIARIES

Consolidated Statements of Operations

(unaudited)

(in thousands, except share and per share data)

 

 

Three Months Ended June 30,

 

 

2022

 

 

 

2021

 

 

 

 

 

Revenue

 

 

 

Product

$

15,142

 

 

$

15,199

 

Royalty and licensing

 

153

 

 

 

41,149

 

Total revenue

 

15,295

 

 

 

56,348

 

Cost of revenue

 

9,835

 

 

 

8,810

 

Gross profit

 

5,460

 

 

 

47,538

 

 

 

 

 

Operating expenses

 

 

 

Sales and marketing

 

6,562

 

 

 

6,304

 

Research and development

 

3,958

 

 

 

3,650

 

General and administrative

 

7,693

 

 

 

6,689

 

Total operating expenses

 

18,213

 

 

 

16,643

 

(Loss) income from operations

 

(12,753

)

 

 

30,895

 

 

 

 

 

Other income and expenses

 

 

 

Interest income

 

14

 

 

 

39

 

Interest expense

 

(453

)

 

 

(607

)

Other income

 

 

 

 

7,252

 

Foreign currency exchange transaction (loss) income

 

(2,432

)

 

 

455

 

Total other (expenses) income

 

(2,871

)

 

 

7,139

 

(Loss) income before income taxes

 

(15,624

)

 

 

38,034

 

Income tax provision

 

(100

)

 

 

(8

)

 

 

 

 

Net (loss) income

$

(15,524

)

 

$

38,042

 

 

 

 

 

Net (loss) income per share:

 

 

 

Basic

$

(0.09

)

 

$

0.21

 

Diluted

$

(0.09

)

 

$

0.21

 

Weighted average common shares outstanding:

 

 

 

Basic

 

180,296,273

 

 

 

177,668,627

 

Diluted

 

180,296,273

 

 

 

180,015,105

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


 

CONFORMIS, INC. AND SUBSIDIARIES

Consolidated Balance Sheets

(in thousands, except share and per share data)

 

 

 

 

 

June 30, 2022

 

December 31, 2021

Assets

 (unaudited) 

 

 

Current Assets

 

 

 

Cash and cash equivalents

$

72,641

 

 

$

100,556

 

Accounts receivable, net

 

9,538

 

 

 

9,079

 

Royalty and licensing receivable

 

155

 

 

 

280

 

Inventories, net

 

16,727

 

 

 

15,204

 

Prepaid expenses and other current assets

 

1,707

 

 

 

1,764

 

Total current assets

 

100,768

 

 

 

126,883

 

Property and equipment, net

 

9,123

 

 

 

10,268

 

Operating lease right-of-use assets

 

6,846

 

 

 

7,536

 

Other Assets

 

 

 

Restricted cash

 

462

 

 

 

562

 

Other long-term assets

 

88

 

 

 

92

 

Total assets

$

117,287

 

 

$

145,341

 

 

 

 

 

Liabilities and stockholder's equity

 

 

 

Current liabilities

 

 

 

Accounts payable

$

7,179

 

 

$

6,557

 

Accrued expenses

 

8,565

 

 

 

9,576

 

Operating lease liabilities

 

1,891

 

 

 

1,830

 

Total current liabilities

 

17,635

 

 

 

17,963

 

Long-term debt, less debt issuance costs

 

20,438

 

 

 

20,355

 

Operating lease liabilities

 

5,784

 

 

 

6,471

 

Total liabilities

 

43,857

 

 

 

44,789

 

Commitments and contingencies

 

 

 

Stockholders' equity

 

 

 

Preferred stock, $0.00001 par value:

 

 

 

Authorized: 5,000,000 shares authorized at June 30, 2022 and December 31, 2021; no shares issued and outstanding as of June 30, 2022 and December 31, 2021

 

 

 

 

 

Common stock, $0.00001 par value:

 

 

 

Authorized: 300,000,000 shares authorized at June 30, 2022 and December 31, 2021; 188,227,075 and 186,042,390 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively

 

2

 

 

 

2

 

Additional paid-in capital

 

634,096

 

 

 

632,513

 

Accumulated deficit

 

(562,406

)

 

 

(530,851

)

Accumulated other comprehensive income (loss)

 

1,738

 

 

 

(1,112

)

Total stockholders' equity

 

73,430

 

 

 

100,552

 

Total liabilities and stockholders' equity

$

117,287

 

 

$

145,341

 



Advertisement